Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Blood Factors, Vaccines and Peptide Antibiotics

Report Code: BIO134A

Publish Date: Oct 2013

Publisher: BCC Publishing

Category: Cell Biology

Customize This Report

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

Report Includes

  • An overview of the markets for major classes of protein with a focus on blood factors, vaccines, and peptide antibiotics.
  • Analyses of market trends, with data from 2011 and 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) for the period 2013 to 2018.
  • Examinations of current successes, including size and sales forecasts for this segment over the next five years.
  • Discussion of the regulatory environment, technological developments and their related strengths and weaknesses, as well as discussion on growing competition and changing customer needs.

INTRODUCTION

STUDY OBJECTIVES

The objective of BCC in conducting this study is to provide an overview of the current and future characteristics of the global market for protein drugs/therapeutics. The key objective is to present a comprehensive analysis and future direction of protein drugs as an important tool in the treatment of various diseases.

This report explores present and future strategies within the protein therapeutics market, which includes peptide hormones, therapeutic enzymes, cytokines, monoclonal antibodies, blood factors, vaccines and peptide antibodies. The improvisation of the market, the setbacks and the needs of the market are discussed in this report. The classifications, manufacturing processes and usage of protein drugs are also portrayed.

A detailed analysis of protein therapeutics industry structure has been conducted. Revenues are broken down by region, by type and by manufacturing method. Sales figures are given for 2011, 2012 and estimated for the five-year period from 2013 through 2018.

The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Widespread research in the field of protein therapeutics has discovered specific functionality that provides therapeutic treatments for various diseases.

R&D spending, along with increasing competition, patent expiries and new technologies are providing a new direction. New advancements, new product launches and a changing lifestyle have caused the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type of technology in light of the new technologies, growing competition, and changing customer needs.

INTENDED AUDIENCE

This study contributes to the areas of market growth in protein therapeutics manufacturers and users. Pharmaceutical biotechnical companies, research institutes, and physicians will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses protein therapeutics in pharmaceutical and biotechnology markets. BCC Research analyzes each market and its applications, regulatory environment, technology, market projections, and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes countries like India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, etc.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors and technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of kinase inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.

BCC ONLINE SERVICES

Now you can locate the hard-to-find information you need on the Internet’s World Wide Web. By directing your browser to BCC Research’s new “home page,” you will be able to do the following:

  • Examine the complete BCC Research catalog of market research reports and place direct orders.
  • Read announcements of recently published reports.
  • Register for its well-known conferences.
  • Request additional information on any BCC research product.
  • Take advantage of special offers.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature.  This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature.  The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Blood Factors, Vaccines and Peptide Antibiotics183Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: SUMMARY2Free
Chapter- 3: OVERVIEW22Free
Chapter- 4: REGULATORY ASPECTS19Free
Chapter- 5: NEW DEVELOPMENTS20Free
Chapter- 6: GLOBAL MARKETS29Free
Chapter- 7: BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS 43Free
Chapter- 8: PATENT ANALYSIS10Free
Chapter- 9: CURRENT SITUATION4Free
Chapter- 10: C. CRAMER & CO. GMBH29Free
Chapter- 11: APPENDIX: ABBREVIATIONS2Free

Related Reports

Environmental Markets for Biotechnology

Published - Aug 2013 | Publisher - Jon Evans | Code - BIO019C

U.S. sales of environmental biotechnology products was valued at $241.2 million in 2012. This is expected to increase at a total compound annual growth rate (CAGR) of 7.9%, with 2013 sales of $261.9 million, rising to $382.3 million in 2018.

Next Generation Sequencing: Emerging Clinical Applications and Global Markets

Published - Jul 2013 | Publisher - John Bergin | Code - BIO126A

The next generation sequencing market reached $231.7 million in 2012. The market is expected to reach $510.7 million in 2013 and $7.6 billion in 2018 for a compound annual growth rate (CAGR) of 71.6%.

Skin Disease Treatment Technologies and Global Markets

Published - May 2013 | Publisher - Paul Evers | Code - PHM127A

The global dermatology markets reached $15.8 billion in 2012. The market is expected to reach $16.1 billion in 2013 and $18.5 billion in 2018 for a CAGR of 2.8%.

Global Markets for Enzyme Inhibitors

Published - Jun 2012 | Publisher - Shalini Shahani Dewan | Code - BIO057B

The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.

Recent Reports

Bioprocess Optimization and Digital Bio-manufacturing: Global Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - BIO170B

The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 and is projected to reach $39.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2024 to 2029.

Global DNA Sequencing: Research, Applied and Clinical Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - BIO045J

The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.

Artificial Intelligence (AI) in Cancer

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO196B

The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Top Trending Reports

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Medical Devices Industry: Competitive Landscape

Published - Nov 2024 | Publisher - BCC Publishing | Code - MDS010C

The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC239C

The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Blood Factors, Vaccines and Peptide Antibiotics
Customize Report